Compare CHEC & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHEC | ANTX |
|---|---|---|
| Founded | 2024 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.5M | 172.9M |
| IPO Year | N/A | 2022 |
| Metric | CHEC | ANTX |
|---|---|---|
| Price | $10.19 | $5.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 6.7K | ★ 353.1K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.91 | $1.00 |
| 52 Week High | $10.56 | $6.91 |
| Indicator | CHEC | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.39 | 58.69 |
| Support Level | $10.15 | $3.91 |
| Resistance Level | $10.47 | $5.13 |
| Average True Range (ATR) | 0.01 | 0.36 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 66.67 | 80.00 |
Chenghe Acquisition III Co is blank check company.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.